Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality

Sanofi is stepping up its long-held interest in antibody-drug conjugates (ADCs). Having first teamed up with Immunogen almost 20 years ago, Sanofi has now joined forces with Seagen to jointly fund and develop three anti-cancer ADCs.